Abstract 1679: Genome-wide Methylation Analysis in Barrett's Esophagus and Esophageal Adenocarcinoma
Enping Xu,Jian Gu,Ernest T. Hawk,Maosheng Huang,Kenneth K. Wang,Jaffer A. Ajani,Xifeng Wu
DOI: https://doi.org/10.1158/1538-7445.am2012-1679
IF: 11.2
2012-01-01
Cancer Research
Abstract:Abstract Esophageal carcinogenesis (EAC) is a multiple-step process involving the accumulation of multiple genetic and epigenetic changes. Barrett's esophagus (BE) is a precursor of EAC. In this study, we performed genome-wide methylation profiling of BE and EAC tissues to identify novel tumor suppressors involved in esophageal carcinogenesis and potential biomarkers for the malignant progression of EAC. Using Illumina's HumanMethylation27 BeadChip microarray, we examined the methylation status of 27,578 CpG sites in 94 normal tissues, 77 BE, and 117 EAC tissues. Hierarchical clustering analysis showed an excellent separation of normal tissues from BE and EAC tissues; however, the clustering of BE and EAC tissues was less clear, suggesting the methylation pattern of BE and EAC was similar and methylation occurs early during the progression of EAC. At the individual gene level, we recapitulated the major tumor suppressors that previously reported to be hypermethylated in BE and EAC, including SFRP1, APC, WIF1, etc. We also identified a large number of novel hypermethylated genes in BE and EAC tissues, in particular, genes of several family proteins, including ADAM peptidase proteins, cadherin and procadherin, and potassium voltage-gated channels. We used pyrosequencing to validate selected genes in these families. For example, in normal, BE and EAC tissue, the methylation frequency of PCDH9 was 0.20%, 24.6% and 29.5% respectively, and the methylation frequency of ADAMTS2 was 4.69%, 37.3% and 32% respectively. In general, there were significant correlations between array and pyrosequencing results. The identified differentially methylated genes may become potential biomarkers for the prediction and early detection EAC among BE patients and molecular targets for prevention and therapy of EAC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1679. doi:1538-7445.AM2012-1679